Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results
Precigen, Inc. (Nasdaq: PGEN) reported third quarter 2020 revenues of $23.6 million, up 29% from $18.3 million in Q3 2019. The net loss narrowed to $29.5 million or $(0.18) per share, improving from $49.1 million or $(0.32) per share a year prior. Year-to-date revenues reached $83.8 million, a 14% increase from $73.7 million in 2019. Key achievements included FDA clearance for the UltraPorator system, dosing the first patient in the PRGN-2009 trial, and advancing UltraCAR-T therapies for ovarian cancer and AML.
- Quarterly revenues rose 29% to $23.6 million.
- Net loss improved to $29.5 million from $49.1 million year-over-year.
- FDA clearance of UltraPorator for UltraCAR-T manufacturing.
- Successful dosing of first patient in PRGN-2009 trial.
- Net loss from continuing operations remains significant at $29.5 million.
- $23.0 million impairment charges due to write-down of goodwill and intangible assets.
GERMANTOWN, Md., Nov. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter and year-to-date financial results for 2020.
Business Highlights:
- Clinical Pipeline and Data Update Conference Call: In light of the substantive progress made in advancing its clinical pipeline, as well as anticipated data disclosures for several key programs, Precigen will host a conference call in early December dedicated to reviewing these important milestones. The Company plans to announce timing and details about the call in the coming weeks;
- UltraPorator™: Precigen announced that the US Food and Drug Administration (FDA) cleared UltraPorator as a manufacturing device for its UltraCAR-T manufacturing process. The Company announced that it has successfully completed technology transfer of the UltraPorator system for the manufacturing of PRGN-3005 in ovarian cancer at the University of Washington/Fred Hutchinson Cancer Research Center and for PRGN-3006 in acute myeloid leukemia (AML) at the Moffitt Cancer Center. UltraPorator is a semi-closed, high-throughput system with a proprietary hardware and software solution designed to significantly reduce processing time and contamination risk, limitations inherent in existing electroporation devices that contribute to current hurdles for viable scale-up and commercialization of certain therapeutic programs;
- PRGN-2009 AdenoVerse™ Immunotherapy: Precigen announced that the first patient has been dosed in the Phase I/II trial for PRGN-2009, a first-in-class, off-the-shelf investigational immunotherapy utilizing the AdenoVerse platform and designed to activate the immune system to recognize and target HPV-positive solid tumors;
- PRGN-3005 UltraCAR-T: Precigen completed dosing of patients in dose level 3 of the intraperitoneal (IP) arm of the Phase 1 clinical trial of PRGN-3005 UltraCAR-T for the treatment of advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer (clinical trial identifier: NCT03907527); and
- PRGN-3006 UltraCAR-T: Precigen completed dosing of patients in dose level 2 of the non-lymphodepletion arm and dose level 1 in the lymphodepletion arm of the Phase 1 trial of PRGN-3006 UltraCAR-T for treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261).
"The Precigen team has made impressive progress this quarter in driving value across our preclinical and clinical pipeline. In particular, we made several advances in our quest to meet unmet needs for patients, including dosing the first patient in our first-in-human study of PRGN-2009 AdenoVerse in HPV-positive solid tumors, and advancing our proprietary UltraPorator system towards clinical implementation," said Helen Sabzevari, PhD, President and CEO of Precigen. "In early December, we are excited to share a comprehensive update on our clinical pipeline progress towards meeting our 2020 goals laid out earlier this year as well as looking forward to the PRGN-3006 presentation at the 2020 meeting of the American Society of Hematology by the trial's Principal Investigator, Dr. David Sallman from the Moffitt Cancer Center."
Third Quarter 2020 Financial Highlights:
- Total revenues of
$23.6 million in 2020 compared to$18.3 million in 2019; - Net loss from continuing operations of
$29.5 million , or$(0.18) per basic share, of which$10.1 million was for non-cash charges in 2020, compared to net loss from continuing operations of$49.1 million , or$(0.32) per basic share, of which$15.7 million was for non-cash charges in 2019; and - Cash, cash equivalents, and short-term investments totaled
$113.1 million as of September 30, 2020.
Year-to-Date 2020 Financial Highlights:
- Total revenues of
$83.8 million in 2020 compared to$73.7 million in 2019; and - Net loss from continuing operations of
$102.8 million , or$(0.63) per basic share, of which$50.6 million was for non-cash charges in 2020 compared to net loss from continuing operations attributable to Precigen of$132.7 million , or$(0.86) per basic share, of which$36.2 million was for non-cash charges in 2019.
Third Quarter 2020 Financial Results Compared to Prior Year Period
Total revenues increased
Research and development expenses decreased
Year-to-Date 2020 Financial Results Compared to Prior Year Period
Total revenues increased
Research and development expenses decreased
Precigen: Advancing Medicine with Precision™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn.
Trademarks
Precigen, UltraPorator, UltraCAR-T, AdenoVerse and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon Precigen's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of Precigen's business, including the timing, pace and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T therapies, and the Company's refocus to a healthcare-oriented business. Although management believes that the plans, objectives and results reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, and actual future results may be materially different from the plans, objectives and expectations expressed. These risks and uncertainties include, but are not limited to, (i) the impact of the COVID-19 pandemic on our clinical trials, businesses, operating results, cash flows and/or financial condition, (ii) ongoing transition efforts following Precigen's recent divestment of several assets and businesses; (iii) Precigen's strategy and overall approach to its business model, its recent efforts to realign its business, and its ability to exercise more control and ownership over the development process and commercialization path; (iv) the ability to successfully enter new markets or develop additional products, including the expected timing and results of investigational studies and preclinical and clinical trials, including any delays or potential delays as a result of the COVID-19 pandemic, whether with its collaborators or independently; (v) the ability to successfully enter into optimal strategic relationships with its subsidiaries and operating companies that it may form in the future; (vi) the ability to hold or generate significant operating capital, including through partnering, asset sales and operating cost reductions; (vii) actual or anticipated variations in operating results; (viii) actual or anticipated fluctuations in competitors' or collaborators' operating results or changes in their respective growth rates; (ix) cash position; (x) market conditions in Precigen's industry; (xi) the volatility of Precigen's stock price; (xii) the ability, and the ability of collaborators, to protect Precigen's intellectual property and other proprietary rights and technologies; (xiii) the ability, and the ability of collaborators, to adapt to changes in laws or regulations and policies, including federal, state, and local government responses to the COVID-19 pandemic; (xiv) outcomes of pending and future litigation; (xv) the rate and degree of market acceptance of any products developed by Precigen, its subsidiaries, collaborations or joint ventures; (xvi) the ability to retain and recruit key personnel; (xvii) expectations related to the use of proceeds from public offerings and other financing efforts; (xviii) estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xix) the challenges inherent in leadership transitions. For further information on potential risks and uncertainties, and other important factors, any of which could cause Precigen's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Precigen's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
For more information, contact:
Investor Contact: Steven Harasym Vice President, Investor Relations Tel: +1 (301) 556-9850 | Media Contact: Glenn Silver Lazar-FINN Partners |
Precigen, Inc. and Subsidiaries | |||||||
(Amounts in thousands) | September 30, 2020 | December 31, 2019 | |||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 27,740 | $ | 65,793 | |||
Short-term investments | 85,358 | 9,260 | |||||
Receivables | |||||||
Trade, net | 19,063 | 20,650 | |||||
Related parties, net | 12 | 600 | |||||
Other | 285 | 4,978 | |||||
Inventory | 10,348 | 16,097 | |||||
Prepaid expenses and other | 8,310 | 6,444 | |||||
Current assets held for sale | — | 110,821 | |||||
Total current assets | 151,116 | 234,643 | |||||
Property, plant and equipment, net | 44,685 | 60,969 | |||||
Intangible assets, net | 65,018 | 68,346 | |||||
Goodwill | 54,237 | 63,754 | |||||
Investments in affiliates | 337 | 1,461 | |||||
Right-of-use assets | 19,296 | 25,228 | |||||
Other assets | 1,497 | 1,362 | |||||
Total assets | $ | 336,186 | $ | 455,763 | |||
Current liabilities | |||||||
Accounts payable | $ | 4,233 | $ | 5,917 | |||
Accrued compensation and benefits | 7,567 | 14,091 | |||||
Other accrued liabilities | 9,355 | 12,049 | |||||
Deferred revenue | 4,144 | 5,697 | |||||
Lines of credit | — | 1,922 | |||||
Current portion of long-term debt | 421 | 31,670 | |||||
Current portion of lease liabilities | 4,584 | 4,182 | |||||
Related party payables | 357 | 51 | |||||
Current liabilities held for sale | — | 47,333 | |||||
Total current liabilities | 30,661 | 122,912 | |||||
Long-term debt, net of current portion | 193,801 | 186,321 | |||||
Deferred revenue, net of current portion | 30,015 | 48,136 | |||||
Lease liabilities, net of current portion | 20,323 | 23,849 | |||||
Deferred tax liabilities | 2,734 | 2,834 | |||||
Other long-term liabilities | 100 | — | |||||
Total liabilities | 277,634 | 384,052 | |||||
Commitments and contingencies | |||||||
Shareholders' equity | |||||||
Common stock | — | — | |||||
Additional paid-in capital | 1,838,919 | 1,752,048 | |||||
Accumulated deficit | (1,781,729) | (1,652,869) | |||||
Accumulated other comprehensive income (loss) | 1,362 | (27,468) | |||||
Total shareholders' equity | 58,552 | 71,711 | |||||
Total liabilities and shareholders' equity | $ | 336,186 | $ | 455,763 | |||
Precigen, Inc. and Subsidiaries | |||||||||||||
(Amounts in thousands, except share and | Three months ended | Nine months ended | |||||||||||
September 30, | September 30, | ||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||
Revenues | |||||||||||||
Collaboration and licensing revenues | $ | 5,223 | $ | 2,296 | $ | 20,259 | $ | 14,717 | |||||
Product revenues | 6,896 | 5,846 | 20,397 | 18,483 | |||||||||
Service revenues | 11,288 | 9,924 | 42,615 | 39,707 | |||||||||
Other revenues | 176 | 233 | 574 | 813 | |||||||||
Total revenues | 23,583 | 18,299 | 83,845 | 73,720 | |||||||||
Operating Expenses | |||||||||||||
Cost of products | 7,296 | 7,906 | 21,526 | 24,130 | |||||||||
Cost of services | 5,891 | 6,550 | 20,197 | 21,860 | |||||||||
Research and development | 12,154 | 25,667 | 45,253 | 80,844 | |||||||||
Selling, general and administrative | 22,300 | 22,187 | 64,057 | 72,486 | |||||||||
Impairment of goodwill | — | 178 | 9,635 | 178 | |||||||||
Impairment of other noncurrent assets | 920 | 448 | 13,326 | 448 | |||||||||
Total operating expenses | 48,561 | 62,936 | 173,994 | 199,946 | |||||||||
Operating loss | (24,978) | (44,637) | (90,149) | (126,226) | |||||||||
Other Expense, Net | |||||||||||||
Unrealized and realized appreciation | — | (3,139) | — | 3,070 | |||||||||
Interest expense | (4,646) | (4,466) | (13,830) | (13,124) | |||||||||
Interest and dividend income | 579 | 883 | 2,025 | 3,268 | |||||||||
Other income, net | 10 | 2,781 | 145 | 671 | |||||||||
Total other expense, net | (4,057) | (3,941) | (11,660) | (6,115) | |||||||||
Equity in net loss of affiliates | (523) | (479) | (1,125) | (1,943) | |||||||||
Loss from continuing operations before | (29,558) | (49,057) | (102,934) | (134,284) | |||||||||
Income tax benefit | 50 | 3 | 130 | 25 | |||||||||
Loss from continuing operations | $ | (29,508) | $ | (49,054) | $ | (102,804) | $ | (134,259) | |||||
Loss from discontinued operations, net of | — | (4,580) | (26,056) | (20,442) | |||||||||
Net loss | $ | (29,508) | $ | (53,634) | $ | (128,860) | $ | (154,701) | |||||
Net loss attributable to the noncontrolling | — | — | — | 1,592 | |||||||||
Net loss attributable to Precigen | $ | (29,508) | $ | (53,634) | $ | (128,860) | $ | (153,109) | |||||
Amounts Attributable to Precigen | |||||||||||||
Net loss from continuing operations | $ | (29,508) | $ | (49,054) | $ | (102,804) | $ | (132,667) | |||||
Net loss from discontinued operations | — | (4,580) | (26,056) | (20,442) | |||||||||
Net loss attributable to Precigen | $ | (29,508) | $ | (53,634) | $ | (128,860) | $ | (153,109) | |||||
Net Loss per Share | |||||||||||||
Net loss from continuing operations | $ | (0.18) | $ | (0.32) | $ | (0.63) | $ | (0.86) | |||||
Net loss from discontinued operations | — | (0.03) | (0.16) | (0.14) | |||||||||
Net loss attributable to Precigen per | $ | (0.18) | $ | (0.35) | $ | (0.79) | $ | (1.00) | |||||
Weighted average shares outstanding, | 165,527,024 | 154,596,257 | 163,318,375 | 153,770,785 | |||||||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-reports-third-quarter-2020-and-year-to-date-financial-results-301168293.html
SOURCE Precigen, Inc.
FAQ
What were Precigen's third quarter 2020 revenues?
How did Precigen's net loss change in Q3 2020?
What key milestones did Precigen achieve in Q3 2020?
What were the year-to-date 2020 financial results for Precigen?
What were the impairment charges Precigen recorded in 2020?
